These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 23317029

  • 21. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
    Oreja-Guevara C, Rovaris M, Iannucci G, Valsasina P, Caputo D, Cavarretta R, Sormani MP, Ferrante P, Comi G, Filippi M.
    Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
    [Abstract] [Full Text] [Related]

  • 22. Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis.
    Nocentini U, Bozzali M, Spanò B, Cercignani M, Serra L, Basile B, Mannu R, Caltagirone C, De Luca J.
    Brain Imaging Behav; 2014 Sep; 8(3):378-86. PubMed ID: 22584774
    [Abstract] [Full Text] [Related]

  • 23. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Khalil M, Enzinger C, Langkammer C, Tscherner M, Wallner-Blazek M, Jehna M, Ropele S, Fuchs S, Fazekas F.
    Mult Scler; 2009 Sep; 15(9):1048-54. PubMed ID: 19556316
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Uddin MN, Lebel RM, Seres P, Blevins G, Wilman AH.
    Mult Scler; 2016 Aug; 22(9):1133-43. PubMed ID: 26503237
    [Abstract] [Full Text] [Related]

  • 26. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.
    Zhang Y, Metz LM, Yong VW, Mitchell JR.
    J Neurol Sci; 2010 Oct 15; 297(1-2):76-81. PubMed ID: 20708201
    [Abstract] [Full Text] [Related]

  • 27. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E, Nakamura K, Lee JC, You X, Sperling B, Rudick RA.
    Mult Scler; 2016 Apr 15; 22(5):668-76. PubMed ID: 26238463
    [Abstract] [Full Text] [Related]

  • 28. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study.
    Kuchling J, Ramien C, Bozin I, Dörr J, Harms L, Rosche B, Niendorf T, Paul F, Sinnecker T, Wuerfel J.
    Mult Scler; 2014 Dec 15; 20(14):1866-71. PubMed ID: 24781284
    [Abstract] [Full Text] [Related]

  • 29. [Sex-related differences in atrophy and lesion load in multiple sclerosis patients].
    Rojas JI, Patrucco L, Besada C, Funes J, Cristiano E.
    Neurologia; 2013 Sep 15; 28(7):389-93. PubMed ID: 23246218
    [Abstract] [Full Text] [Related]

  • 30. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 15; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S, Khalid F, Weiner HL, Chitnis T, Healy BC, Bakshi R.
    J Neurol Sci; 2017 Dec 15; 383():221-229. PubMed ID: 29146095
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.